The Commercialisation Gap That Conventional Venture Building Cannot Close
Corporate venture building in Singapore is often framed around software, fintech, and business-model innovation—sectors where a concept-validation sprint can produce a minimum viable product in months. Deep tech operates on a different clock. Longer development timelines, higher capital requirements, and more complex pathways to market adoption make the standard venture-studio playbook insufficient on its own.
That is the gap ASTAR is targeting with the expansion of **AStartCentral (A*SC) 2.0**, unveiled in September 2026. The platform, which marks its tenth anniversary this year, has supported more than 100 ventures that collectively raised over S$1.6 billion in capital and created more than 1,800 jobs. The 2.0 iteration doubles the physical footprint from 10,000 to 18,000 square feet and introduces sector-specific venture-building pathways—not just generic incubation.
Why Sector-Specific Pathways Change the Economics
Generic accelerators provide mentorship, workspace, and introductions. Deep-tech ventures need something more granular: laboratories with contamination controls, advanced prototyping equipment, pre-compliance testing infrastructure, and access to research scientists who understand the technology’s failure modes.
By embedding those capabilities inside the venture-building platform, A*SC 2.0 reduces the fixed-cost burden that typically forces deep-tech founders to spend their first S$2–3 million on infrastructure rather than customer discovery. The expanded life-sciences facilities, for example, have doubled from 4,000 square feet of open bench space to 8,000 square feet of dedicated laboratory suites, designed to strengthen intellectual-property protection and reduce cross-contamination risk.
That may sound like operational detail, but it has strategic consequences. When a deep-tech venture can access compliant lab space without building it, the effective cost of starting the company falls—and the range of research projects that can be commercialized widens.
The Corporate Interface: Where A*STAR Meets Venture Building
A*SC is not a corporate venture-building programme in the narrow sense; it is a public research-to-venture pipeline. But its relevance to corporate venture building is direct. Large companies looking to build new deep-tech businesses—whether in specialty chemicals, advanced manufacturing, or health sciences—need de-risked technology assets and founders who can operate inside a corporate ecosystem.
ASC 2.0 positions itself as the upstream supplier of those assets. Ms Irene Cheong, Assistant Chief Executive for Innovation and Enterprise at ASTAR, framed the next phase as helping founders move “beyond commercialisation towards international growth” through sector-specific pathways and expanded infrastructure. For corporates, that means a pool of ventures that have already survived the laboratory stage and are entering the market-validation phase—exactly where corporate venture builders can add distribution, regulatory knowledge, and customer access.
The Portfolio Reality: 100 Ventures, S$1.6 Billion Raised
The headline numbers matter, but the composition of the portfolio matters more. A*SC’s decade of operation has produced ventures across AI and digital infrastructure, biotechnology, and engineering—sectors that align with Singapore’s manufacturing and research strengths. The 2.0 platform is designed to increase the share of those ventures that scale globally from Singapore, rather than being acquired early or relocating abroad.
That ambition carries a structural tension. Deep-tech venture building requires patient capital and long validation cycles, while corporate venture builders are under pressure to show commercial traction within a fiscal year. A*SC’s model partially resolves this by externalizing the early-stage infrastructure cost and providing venture-building support through public funding—leaving the corporate partner to focus on the commercial acceleration phase.
The unanswered question for 2026 is whether the sector-specific pathways will produce a visible cohort of globally competitive deep-tech companies from Singapore, or whether the bottleneck simply moves downstream—from lab access to late-stage growth capital. Either way, A*SC 2.0 is the most concrete attempt in the region to treat deep-tech venture building as an industrial process rather than a series of fortunate accidents.
